Business
Faron Pharmaceuticals Ltd: Grant of Options
TURKU, FI / ACCESS Newswire / December 2, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that the Company's board has ...
About this update from Faron Pharmaceuticals Oy
[{"type":"text","content":"TURKU, FI / ACCESS Newswire / December 2, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that the Company's board has confirmed the grant of a total of 180,000 options over ordinary shares in the Company ("Options") under the Company's Share Option Plan 2019.","length":409,"tagName":"p"},{"type":"text","content":"The Options have been allocated under the Share Option Plan 2019 and are exercisable between 1 December 2026 and 1 December 2031, vesting 25% per annum over four years. The exercise price for Options allocated under the Share Option plan is €2.26 per share, which is calculated based on the average price per share at which the ordinary shares in the Company have been traded on AIM for 90 days preceding the allocation date of 1 December 2025. The terms of the Share Option Plan 2019 are available on the Company's website at https://faron.com/wp-content/uploads/2025/04/20250321_Share-Option-Plan-2019_Rules_EN_clean.pdf","length":626,"tagName":"p"},{"type":"text","content":"The granted 180,000 Options entitle the option holders to subscribe for a total of 180,000 new ordinary shares in the Company, if exercised in full, and represent 0.16% of the fully diluted ordinary share capital of the Company.","length":228,"tagName":"p"},{"type":"text","content":"Included in the number of Options granted are the following Options which were issued to directors, other persons discharging managerial responsibilities ("PDMRs") and Company personnel:","length":196,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"1","rowspan":"1","style":"border-color:#DDDDDD;border-width:1px;padding:2px 4px;vertical-align:bottom;","val":[]},{"colspan":"1","rowspan":"1","style":"border-color:#DDDDDD;border-width:1px;padding:2px 4px;text-align:right;vertical-align:top;","val":[]}]},{"val":[{"colspan":"1","rowspan":"1","style":"border-color:#DDDDDD;border-width:1px;padding:2px 4px;vertical-align:top;","val":[{"type":"text","content":"Other PDMR","length":10,"tagName":"p"}]},{"colspan":"1","rowspan":"1","style":"border-color:#DDDDDD;border-width:1px;padding:2px 4px;text-align:right;vertical-align:top;","val":[]}]},{"val":[{"colspan":"1","rowspan":"1","style":"border-color...